Priya Nalawade’s Post

💡 Join Crown Bioscience for an upcoming webinar to explore the significant hurdle of cancer drug resistance, one of the greatest challenges in developing effective cancer therapeutics. 💊 Dr. Rajendra Kumari will discuss the evolving landscape of drug resistance, focusing on preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights. Attendees will gain insights into specific models developed to study resistance to targeted therapies and immunotherapeutics, along with their features and practical applications for predicting clinical outcomes. ➡️ Learn more + register here: https://buff.ly/4eagwr7 #DrugDevelopment #DrugDiscovery #DrugResistance #Oncology #TherapeuticAreas #OncologyDrugDevelopment #CancerTherapy #PreClinical #CellAndGeneTherapies

Antibody-drug conjugates (ADCs) have emerged as a revolutionary approach to cancer treatment, enabling the targeted delivery of cytotoxic drugs to cancer cells while minimizing systemic toxicity. The global ADC market is witnessing remarkable growth, fueled by advancements in linker technologies, extensive research and development efforts, and the rising global incidence of cancer. In Taiwan, several companies are actively engaged in the development and manufacturing of ADCs, contributing significantly to the global oncology landscape. Download our FREE eBook: 𝐀 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐓𝐚𝐢𝐰𝐚𝐧'𝐬 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐀𝐃𝐂 𝐏𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 for more insights. DOWNLOAD HERE: https://lnkd.in/gDEb2HSH #imagineyourimpact #antibodydrugconjugates #ADC2025

𝗞𝗮𝗽𝗮𝗱𝗶 𝗮𝗻𝗱 𝗡𝗲𝘅𝘁 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗧𝗲𝗮𝗺 𝗨𝗽 𝗳𝗼𝗿 𝗦𝗶𝘅 𝗣𝗵𝗮𝘀𝗲 𝟭 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹𝘀 Exciting news! Next Oncology and Oncobay have joined forces to launch a series of groundbreaking Phase 1 clinical trials. Together, we are pushing the boundaries of cancer treatment! These trials will focus on evaluating novel immuno-oncology therapies designed to unleash the immune system's power against cancer. By combining our expertise, we aim to develop safer and more effective treatments for patients battling this relentless disease. Read the full press-release here: https://lnkd.in/dNhYazmU #CancerResearch #ImmunoOncology #ClinicalTrials #Collaboration #pressrelease #article #oncology #Kapadi #clinicaltrials #clinicalresearch #pharma #biotech

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery. https://hubs.li/Q02pvCkq0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

Delve into the molecular intricacies of cancer with DRUG-seq, an affordable and efficient RNA-seq application that is changing the landscape of oncology drug discovery. This state-of-the-art technology drives innovation in investigating mechanisms of drug action, profiling drug responses, discovering biomarkers, and untangling tumor heterogeneity. Contact us to find out how you can use Champions' new DRUG-seq platform to generate fast insights in drug discovery: https://hubs.li/Q02HsjHk0 #DRUGseq #OncologyResearch #CancerResearch #RNAseq #MechanismOfAction #DrugResponse #DrugResistance #BiomarkerDiscovery #TumorHeterogeneity #Oncology #Cancer #PrecisionMedicine #DrugDiscovery #endpointspotlight

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/R6k34m 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/ZU94BL #oncology #oncologyresearch #ProductCitation

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/GsLeHp 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/dqZJEH #oncology #oncologyresearch #ProductCitation

🌟A recent study using our #ResearchChemicals identified the enzyme DECR2 as a promising therapeutic target in treating preclinical models of castration-resistant #ProstateCancer. Read the full study in the British Journal of Cancer: https://okt.to/BlUTnk 💡Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/m4QyZ1 #oncology #oncologyresearch #ProductCitation

If you’re developing an antibody-drug conjugate (ADC) to treat cancer, you need data-backed answers to these questions: -Is the antibody being internalized? -Where’s the therapeutic trafficked? -Is the drug actually killing cancer cells? And that’s where imaging and bioassays come in. Through a suite of imaging assays, our team of scientists can help you select your lead candidates from hundreds to a handful, making sure that the best candidate progresses to IND filing. We can provide real-time data on internalization, trafficking, tumor-cell killing, and a host of other cell functions. All of these powerful imaging assays and analyses come early on in the development process because we believe in starting smart, so you can progress fast to IND and beyond. Find out more about our assay capabilities here: https://lnkd.in/ez2YMCCD #microscopy #drugdevelopment #CDMO #CRO #ADCCDMO

IOS-1002 is a multi-functional agent based on a naturally occurring human leukocyte antigen that targets multiple immune checkpoints ( LILRB1 (ILT2), LILRB2 (ILT4) and KIR3DL1) to activate both innate and adaptive immune cells. IOS-1002 (formerly iosH2) is described as an open format (peptide free conformation) and expression- and stability-optimized HLA-B57-B2m-IgG4_Fc fusion protein.